204 related articles for article (PubMed ID: 6644332)
1. Modulation of natural killing activity by lymphoblastoid interferon in cancer patients.
Koren HS; Brandt CP; Tso CY; Laszlo J
J Biol Response Mod; 1983; 2(2):151-65. PubMed ID: 6644332
[TBL] [Abstract][Full Text] [Related]
2. Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon.
Lotzová E; Savary CA; Quesada JR; Gutterman JU; Hersh EM
J Natl Cancer Inst; 1983 Nov; 71(5):903-10. PubMed ID: 6580490
[TBL] [Abstract][Full Text] [Related]
3. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
[TBL] [Abstract][Full Text] [Related]
4. Regulation of human natural killer cell cytotoxicity by recombinant leukocyte interferon clone A.
Lotzová E; Savary CA; Gutterman JU; Quesada JR; Hersh EM
J Biol Response Mod; 1983; 2(5):482-96. PubMed ID: 6644351
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory activities of human leukocyte interferon in advanced cancer patients.
Bash JA; Teitelbaum D; Sreevalsan T; Neefe JR
J Biol Response Mod; 1983; 2(1):57-65. PubMed ID: 6606019
[TBL] [Abstract][Full Text] [Related]
6. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
7. Immunological effects of recombinant interferon-alpha 2 in cancer patients.
Hengst JC; Kempf RA; Kan-Mitchell J; Pham AT; Grunberg SM; Kortes VL; Mitchell MS
J Biol Response Mod; 1983; 2(6):516-27. PubMed ID: 6663321
[TBL] [Abstract][Full Text] [Related]
8. Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity.
Edwards BS; Hawkins MJ; Borden EC
Cancer Res; 1984 Jul; 44(7):3135-9. PubMed ID: 6586292
[TBL] [Abstract][Full Text] [Related]
9. Intraperitoneal administration of human recombinant interferon-alpha in patients with ovarian cancer: effects on lymphocyte phenotype and cytotoxicity.
Lichtenstein A; Spina C; Berek JS; Jung T; Zighelboim J
Cancer Res; 1988 Oct; 48(20):5853-9. PubMed ID: 3167841
[TBL] [Abstract][Full Text] [Related]
10. Correlation between in vitro and systemic effects of native and recombinant interferons-alpha on human natural killer cell cytotoxicity.
Edwards BS; Hawkins MJ; Borden EC
J Biol Response Mod; 1983; 2(5):409-17. PubMed ID: 6644345
[TBL] [Abstract][Full Text] [Related]
11. Modulation of murine natural killer cell activity in vitro and in vivo by recombinant human interferons.
Brunda MJ; Rosenbaum D
Cancer Res; 1984 Feb; 44(2):597-601. PubMed ID: 6692364
[TBL] [Abstract][Full Text] [Related]
12. Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials.
Ernstoff MS; Fusi S; Kirkwood JM
J Biol Response Mod; 1983; 2(6):540-7. PubMed ID: 6607324
[TBL] [Abstract][Full Text] [Related]
13. In vivo priming effects of interferon-beta ser on NK activity of peripheral blood mononuclear cells in cancer patients.
Fujimiya Y; Wagner RJ; Groveman S; Sielaff K; Kohsaka T; Nakayama M
Ther Immunol; 1995 Feb; 2(1):15-22. PubMed ID: 7553067
[TBL] [Abstract][Full Text] [Related]
14. Suppression of natural killer cell cytotoxicity in the peripheral blood of patients receiving interferon therapy.
Spina CA; Fahey JL; Durkos-Smith D; Dorey F; Sarna G
J Biol Response Mod; 1983; 2(5):458-69. PubMed ID: 6644350
[TBL] [Abstract][Full Text] [Related]
15. Regulation of natural and antibody-dependent cellular cytotoxicity by staphylococcal enterotoxin A.
Kimber I; Bakács T; Moore M
Clin Exp Immunol; 1983 Oct; 54(1):39-48. PubMed ID: 6616973
[TBL] [Abstract][Full Text] [Related]
16. Systemic administration of human leukocyte interferon to melanoma patients. II. Cellular events associated with changes in natural killer cytotoxicity.
Golub SH; D'Amore P; Rainey M
J Natl Cancer Inst; 1982 May; 68(5):711-7. PubMed ID: 6175788
[TBL] [Abstract][Full Text] [Related]
17. Defective NK cell activity following thermal injury.
Klimpel GR; Herndon DN; Fons M; Albrecht T; Asuncion MT; Chin R; Stein MD
Clin Exp Immunol; 1986 Nov; 66(2):384-92. PubMed ID: 3493101
[TBL] [Abstract][Full Text] [Related]
18. Systemic administration of human leukocyte interferon to melanoma patients. III. Increased helper:suppressor cell ratios in melanoma patients during interferon treatment.
Karavodin LM; Golub SH
Nat Immun Cell Growth Regul; 1983-1984; 3(4):193-202. PubMed ID: 6241293
[TBL] [Abstract][Full Text] [Related]
19. Regulation of natural killer cytotoxicity by recombinant alpha interferons. Augmentation by IFN-alpha 7, an interferon similar to IFN-alpha J.
Platsoucas CD; Fox FE; Oleszak E; Fong K; Nanno M; Ioannides CG; Trotta PP
Anticancer Res; 1989; 9(4):849-58. PubMed ID: 2817813
[TBL] [Abstract][Full Text] [Related]
20. Effect of interferon on antibody-dependent cellular cytotoxicity (ADCC) in chickens.
Mándi Y; Bakay M; Béládi I
Acta Microbiol Hung; 1984; 31(2):127-33. PubMed ID: 6464658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
